This document is an excerpt from the EUR-Lex website
Document 52008XC0125(01)R(01)
Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007 ( OJ C 19, 25.1.2008 )
Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007 ( OJ C 19, 25.1.2008 )
Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007 ( OJ C 19, 25.1.2008 )
IO C 107, 13.4.2012, p. 14–14
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
13.4.2012 |
EN |
Official Journal of the European Union |
C 107/14 |
Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007
( Official Journal of the European Union C 19 of 25 January 2008 )
2012/C 107/08
On page 4, third and fourth rows of the table:
for:
|
‘12.12.2007 |
Olanzapine Teva |
Olanzapine |
|
EU/1/07/427/001-022 |
Film-coated tablet |
N05AH03 |
14.12.2008 |
||||||
|
EU/1/07/427023-037 |
Orodispersible tablets |
||||||||||||
|
13.12.2007 |
Atripla |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate |
|
EU/1/07/430/001 |
Film-coated tablet |
J05AR06 |
18.12.2008’ |
read:
|
‘12.12.2007 |
Olanzapine Teva |
Olanzapine |
|
EU/1/07/427/001-022 |
Film-coated tablet |
N05AH03 |
14.12.2007 |
||||||
|
EU/1/07/427023-037 |
Orodispersible tablets |
||||||||||||
|
13.12.2007 |
Atripla |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate |
|
EU/1/07/430/001 |
Film-coated tablet |
J05AR06 |
18.12.2007’ |